First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE.
Balsat M, et al. Among authors: alcazer v.
Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9.
Leuk Res. 2023.
PMID: 37230027